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Background: Numerous epidemiology studies on dyslipidemia have been conducted in China. However, a
nationally representative estimate for dyslipidemia prevalence is lacking. The aim of this study is to appraise
the nationwide prevalence, awareness, treatment, and control rates of dyslipidemia in adults in China.
Methods: We performed a systematic review of the related observational studies published since 2003 by
searching English and Chinese literature databases. Meta-analyses were conducted in eligible studies using a
random effect model to summarize the dyslipidemia prevalence, awareness, treatment, and control rates. Heterogeneity
and publication bias were analyzed. Sensitivity analyses were performed to explain heterogeneity and examine the
impact of study quality on the results of meta-analyses.
Results: Thirty-eight papers were included for meta-analyses, with a total sample size of 387,825. The prevalence,
awareness, treatment, and control rates of dyslipidemia were 41.9% (95% CI: 37.7% – 46.2%), 24.4% (95% CI:
14.4% – 38.4%), 8.8% (95% CI: 7.7% – 10.0%), and 4.3% (95% CI: 4.1% – 4.5%), respectively. The prevalence of
hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, low levels of high-density lipoprotein
cholesterol, and high levels of low-density lipoprotein cholesterol were 10.1% (95% CI: 5.8% – 16.9%), 17.7%
(95% CI: 14.0% – 22.1%), 5.1% (95% CI: 3.1% – 8.2%), 11.0% (95% CI: 8.0% – 15.0%), and 8.8% (95% CI: 4.1% – 17.8%),
respectively. Sensitivity analyses revealed that males had a higher prevalence of dyslipidemia (43.2%) than females
(35.6%). Study samples of age 30 and above in the eastern region tended to have higher prevalence of dyslipidemia.
The quality of the studies has a slight impact on the pooled estimates.
Conclusions: The overall pooled prevalence of dyslipidemia in Chinese adults was estimated to be 41.9%, with males
having a higher rate than females.
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Dyslipidemia represents one of the major risk factors for
atherosclerosis affecting arteries of large and medium
size and consequently causing ischemia in the brain, heart,
or legs. Coronary artery disease and cerebral stroke repre-
sent the major causes of morbidity and mortality among
elderly and middle aged subjects [1]. The prevalence of dys-
lipidemia has increased dramatically in Chinese cities with
lifestyle changes over the past decade, and cardiovascular* Correspondence: sctan@sg.imshealth.com
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Chinese adults [2].
Surveys investigating the epidemiological data of
dyslipidemia in Chinese adults have been published, but
the results vary due to diverse populations of different
regions and the use of different diagnosis criteria [2]. An
overall appraisal of dyslipidemia epidemiology nation-
wide in China would potentially benefit future research
and policy discussions. We therefore performed meta-
analyses by a comprehensive systematic review of all
available evidence to synthesize the current dyslipidemia
prevalence, awareness, treatment, and control among
Chinese adults.Ltd. This is an Open Access article distributed under the terms of the Creative
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Search strategy and eligibility criteria
Based on the MOOSE guideline [3], we identified epi-
demiological studies on dyslipidemia in Chinese adults
published in English or Chinese between January 2003
and August 2013. The search strategy comprised of a
search of Western electronic databases (including Medline,
Embase, and CINAHL) and a search of Chinese databases
(including SinoMed, CNKI, and Wanfang Data). We used
the search terms “dyslipidemia”, “hyperlipidemia”, “epi-
demiology”, “incidence”, “prevalence”, “awareness rate”,
“treatment rate”, “control rate”, “China or Chinese”, and
these terms’ variants and combinations.
Eligible studies had to have reported any of the fol-
lowing epidemiological data related to dyslipidemia in
sampled populations of Chinese subjects: prevalence,
awareness rate, treatment rate, and control rate. The
diagnosis criteria was based on the Chinese Guidelines
on Prevention and Treatment of Dyslipidemia in
Adults [2], which defined dyslipidemia as any one of
the following four conditions: hypercholesterolemia
(total cholesterol (TC) ≥ 6.22 mmol/L); hypertriglyc-
eridemia (triglycerides (TG) ≥2.26 mmol/L); low levels
of high-density lipoprotein cholesterol (HDL-C <
1.04 mmol/L); high levels of low-density lipoprotein
cholesterol (LDL-C ≥ 4.14 mmol/L).
Dyslipidemia awareness was defined as a self-report of
any prior laboratory diagnosis of dyslipidemia. Treat-
ment was defined broadly as interventions including
medication, diet, exercise, and monitoring to manage
dyslipidemia. Participants were considered to have con-
trolled dyslipidemia if their serum TC, TG, LDL-C, and
HDL-C were within the normal ranges as defined above
based on the 2007 Chinese guidelines.
We also applied the following exclusion criteria in
filtering the identified publications:
 Non-human studies
 Non-research based publications such as press
releases, newsletters, forum discussions, etc.
 Non-epidemiological studies such as basic science
research on dyslipidemia.
 Studies that did not disclose when the data was
collected, sample size, or denominator for each
reported prevalence or rate.
 Studies that investigated specific populations such as
military, prisoners, specific ethnic groups, etc.
 Studies that did not apply the diagnosis criteria
published in the 2007 Chinese Guidelines on
Prevention and Treatment of Dyslipidemia in Adults.
Study identification and data extraction
We identified relevant studies by searching electronic
databases, scanning reference lists, and consulting clinicalexperts in dyslipidemia. Additionally, studies presented
at key conference proceedings were identified. Two re-
viewers independently examined all the titles and abstracts
of the studies retrieved from the searches for potentially
eligible studies, then the full text of all potentially relevant
citations were obtained and independently assessed by the
reviewers to confirm whether they met the inclusion cri-
teria. The results were checked and discussed by the two
reviewers to agree upon a final list of included studies.
Using a standardized and predesigned data collection
form, all relevant data in each included paper were ex-
tracted by two reviewers independently. The data extracted
were cross-checked and any unresolved discrepancies were
referred to a third reviewer. Where necessary, inputs of a
clinical expert advisor were solicited to facilitate discussions
among the reviewers.
For each included study, we extracted general informa-
tion (including authors, year, title, type of publication,
etc.), study characteristics (including study design, popu-
lation, location, diagnosis criteria, sample size, etc.),
participants’ characteristics (including age, sex, type of
dyslipidemia, etc.). We further recorded the numbers of
people with any one type of dyslipidemia condition and
reported awareness, treatment, and control rates. The
data stratified by sex and dyslipidemia types, where
available, were also extracted.
To inform the appropriateness of included studies in
the meta-analysis and later evaluate the strength of the
evidence, the two reviewers independently assessed and
agreed on the quality of each included study using the
quality assessment checklist for epidemiological studies
[4]. The checklist assesses the quality of studies on a
scale of 0 (the worst) to 18 (the best) using predefined
criteria on both internal and external validities [4].
Statistical analyses and heterogeneity test
Pooled estimates of the dyslipidemia prevalence, aware-
ness rate, treatment rate, and control rate and their corre-
sponding 95% confidence intervals (CI) were calculated
based on the random effect model [5] and stratified by sex
and age group (over 18 or over 30 years) where applicable.
Heterogeneity between studies was evaluated with the
Cochran’s Q test and I2 statistic, which describes the per-
centage of variation across studies (values of 25%, 50%,
and 75% indicate low, moderate, and high degrees of
heterogeneity, respectively) [6,7]. Subgroup analyses were
performed to investigate potential sources of heterogeneity
from different geographical regions and types of dyslipid-
emia. Publication bias was evaluated by using the funnel
plots method. Furthermore, sensitivity analyses were per-
formed to evaluate the influence of particular study on a
pooled estimate, which was recalculated by omitting a
study each time. Independent or paired t-tests were used
as appropriate, and a significant difference was reported if
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performed using SPSS version 20.0 (SPSS Inc, Chicago,
USA) and Comprehensive Meta-Analysis software version
2.0 (Biostat, Englewood, USA).
Results
Characteristics of included studies
Our searches retrieved 7669 citations. Of these, 6800
were excluded after reading the abstracts, and 831 were
further excluded after assessing the full papers, leaving
38 eligible papers for inclusion in our review and ana-
lyses (Figure 1) [8-45], which involved a total of 387,825
Chinese people.
Among the 38 included papers, 36 were written in
Chinese and two were written in English; 33 studies
were cross-sectional surveys and five studies employed
census surveys or other designs; 18 studies were con-
ducted in eastern China, 10 studies were conducted in
central China, eight studies were conducted in western
China, and two surveys crossed regions nationwide
(Table 1) [8-45].
Study quality was assessed for the 38 included papers.
Four papers had quality scores between eight and 10
points, 13 papers had scores between 11 and 13 points,
and 21 papers had scores between 14 and 16 points.
Overall study quality was upper-middle and high, and
the study quality did not differ significantly among the
included studies.
Prevalence of dyslipidemia
Twenty-eight papers reported the total numbers of par-
ticipants in the studies and those who were diagnosedFigure 1 Flow chart of screening and inclusion of studies for review awith dyslipidemia (Figure 2). The pooled prevalence of
dyslipidemia in Chinese adults was 41.9% (95% CI:
37.7% – 46.2%). The t-tests showed there were no statis-
tically significant differences between subgroups strati-
fied by age and geographic region (Tables 2 and 3);
however, the pooled prevalence of dyslipidemia in males
(43.2%) was higher than in female (35.6%) with statistical
significance (t = 3.08, p < 0.05).
In terms of the different types of dyslipidemia, the
pooled prevalence estimates of hypercholesterolemia
(TC), hypertriglyceridemia (TG), mixed hyperlipidemia
(TC + TG), low levels of high-density lipoprotein choles-
terol (HDL-C), and high levels of low-density lipoprotein
cholesterol (LDL-C) are 10.1% (95% CI: 5.8% – 16.9%),
17.7% (95% CI: 14.0% – 22.1%), 5.1% (95% CI: 3.1% –
8.2%), 11.0% (95% CI: 8.0% – 15.0%), and 8.8% (95% CI:
54.1% – 17.8%), respectively. There were no significant
differences between age groups within each type of dys-
lipidemia condition (Table 4 and Additional file 1).Dyslipidemia awareness, treatment, and control
Using the dyslipidemia awareness rates reported in four
studies, we arrived at a pooled estimate of 24.4% (95%
CI: 14.4% – 38.4%). Based on the reported dyslipidemia
treatment rates in two studies, we estimated a pooled
treatment rate of 8.8% (95% CI: 7.7% – 10.0%). There
were no significant differences between males and fe-
males in terms of dyslipidemia awareness and treatment
rates (Table 5). Only one paper reported a dyslipidemia
control rate, which was 4.3% (3.1% for males and 5.5%
for females).nd analysis.
Table 1 Characteristics of included studies
Author Year Region Age range Number of participants Number of patients diagnosedwith dyslipidemia
Score of quality
assessment
Luo R 2009 Chongqing 18-59 y 20000 6464 12
Guo MH 2011 Beijing 18-79 y 6790 3231 10
Li Y 2008 Beijing 18-79 y 2776 1269 15
Luo WP 2010-2011 Xinjiang ≥ 18 y 2999 2277 14
You AG 2007-2008 Henan ≥ 18 y 20194 - 15
Li JH 2010 National ≥ 18 y 97409 - 15
Mo J 2010 Guangdong ≥ 18 y 3577 2173 16
Pang QY 2006 Henan ≥ 18 y 984 314 9
Pang QY 2007 Henan ≥ 18 y 10127 4392 11
Li JH 2010 National ≥ 18 y 97409 51818 15
Chen YY 2010 Jiangxi ≥ 18 y 3000 1821 14
Zhang XW 2010 Zhejiang ≥ 18 y 17437 8694 14
Li XH 2007-2008 Gansu > 18 y 3038 793 14
Hu XL - Zhejiang > 18 y 2036 - 12
Li SL 2007-2008 Shanxi 20-74 y 1286 459 14
Gao B 2007-2008 Shanxi 20-74 y 3298 1106 15
Jin LZ 2007 Guangdong 20-74 y 1134 - 12
Li J 2009 Beijing 20-78 y 4332 1008 13
Wang JH 2007 Beijing ≥ 20 y 10054 - 13
Fu YY 2007 Beijing ≥ 20 y 10054 3373 16
Yin L 2008-2009 Hunan > 20 y 1544 695 8
Fu YY 2007 Beijing > 20 y 9786 3347 14
Guang ZJ 2011 Beijing 21-91 y 3340 993 14
Liu XY 2008 Ningxia ≥ 25 y 1275 619 14
Yuan XH - Guangdong > 30 y 1053 465 8
Liao XY 2010 Sichuan 35-70 y 2032 474 14
Wang CJ - Henan 35-78 y 16926 7480 14
Shao YQ 2008 Zhejiang > 35 y 7194 - 15
Zhou WJ 2008-2009 Jiangsu > 35 y 2102 922 14
Li J 2009 Shandong > 35 y 1972 - 15
Li Y 2008 Hubei > 35 y 9865 2794 16
Gao Y 2011 Jilin 40-70 y 1332 618 12
Liu DW - Henan ≥ 45 y 4779 - 12
Zhao YZ - Sichuan > 45 y 200 113 11
Wu ZF 2007-2008 Tianjin 50-94 y 1424 - 11
Sheng L 2009 Beijing > 60 y 2685 - 13
Hu XZ 2007 Henan > 60 y 1247 347 13
Liang YQ 2011 Guangdong > 60 y 1135 680 12
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Two studies were assessed with a quality score of eight,
the lowest among the included studies. In the sensitivity
analysis, omitting these two studies resulted in a slight
change in the pooled dyslipidemia prevalence estimate,41.7% from 41.9%. The pooled prevalence of TC, TG,
HDL-C, and LDL-C changed to 9.4%, 17.0%, 10.7%, and
8.3% from 10.1%, 17.7%, 11.0%, and 8.8%, respectively. Fun-
nel plots were produced for the prevalence of each type of
dyslipidemia (see the Additional file 1). Asymmetric funnels
Figure 2 Forest plot of 28 studies’ reported prevalence of dyslipidemia.
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Table 2 Prevelance of dyslipidemia by different age groups
Age range Number of studies Total numbersof participants Median (%) Minimum (%) Maximum (%)
Pooled prevalence
(%) (95% CI)
≥ 18 y 19 203052 43.4 23.3 75.9 42.4 (37.2 ~ 47.7)
≥ 30 y 9 35892 44.2 23.3 59.9 40.9 (33.7 ~ 48.5)
Total 28 238944 44 23.3 75.9 41.9 (37.7 ~ 46.2)
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degree of heterogeneity was observed in the pooled
dyslipidemia prevalence (I2 = 49.9%, Q = 1.00, P < 0.001),
awareness rate (I2 = 49.9%, Q = 0.99, P < 0.001), and treat-
ment rate (I2 = 38.0%, Q = 0.721, P = 0.098).
Discussion
Our systematic review included 38 observational studies
conducted in the past decade, covering most of the re-
gions in China, and involving a total of 387,825 partici-
pants, representing the adult Chinese population. The
pooled estimates from the meta-analyses showed high
prevalence of dyslipidemia and low awareness, treat-
ment, and control rates. The study and results are
timely, as currently there is a lack of published up-to-
date nationwide epidemiological data of dyslipidemia to
support the evidence-based approach and management
of dyslipidemia in China.
The pooled estimate of dyslipidemia prevalence among
Chinese adults is 41.9%, which has more than doubled
in the last 10 years [46], approaching the reportedTable 3 Prevalence of dyslipidemia by different regions and s
Groups Number of studies Total numberof participants M
≥ 18 y
Sex Male 15 80145 4
Female 15 96864 3
Region Eastern China 8 58092 4
Central China 4 15655 4
Western China 6 31896 3
≥ 30 y
Sex Male 3 5442 2
Female 3 7772 3
Region Eastern China 3 4290 4
Central China 4 29370 3
Western China 2 2232 3
Total
Sex Male 18 85587 4
Female 18 104636 3
Region Eastern China 11 62382 4
Central China 8 45025 4
Western China 8 34128 3prevalence of 53% from the US National Health and
Nutrition Examination Survey 2003–2006 [47]. The ob-
served increase of dyslipidemia prevalence in China could
possibly be attributed to the increasingly aging population
and dramatic lifestyle changes coupled with economic
growth, especially changes in cigarette smoking, dietary,
and alcohol drinking behaviors among the general
population [48].
The study discovered that hypertriglyceridemia (TG)
was the most prevalent form of dyslipidemia, with a
pooled estimate of 17.7%, followed by low levels of blood
high-density lipoprotein cholesterol (HDL-C) (11.0%),
hypercholesterolemia (TC) (10.1%), high levels of low-
density lipoprotein cholesterol (LDL-C) (8.8%), and
mixed hyperlipidemia (TC + TG) (5.1%). As dyslipid-
emia is one of the well-established risk factors for
cardiovascular diseases [47], these results highlight the
extensive need for appropriate interventions, both
clinical and non-clinical, to treat all types of dyslipid-
emia. In addition, other considerations such as im-
proving general awareness about dyslipidemia amongexes
edian (%) Minimum (%) Maximum (%) Pooled prevalence(%) (95% CI)
4.3 25.8 68.9 45.6 (40.0 ~ 51.4)
3.7 14.6 56.4 35.9 (29.5 ~ 42.8)
0 23.3 60.7 40.0 (32.6 ~ 47.9)
4.2 31.9 60.7 45.1 (35.2 ~ 55.5)
4.6 26.1 75.9 41.9 (28.9 ~ 56.1)
6.2 24.9 45.3 31.5 (20.7 ~ 44.8)
0.2 29.9 43 34.1 (26.1 ~ 43.3)
4.2 43.9 59.9 49.3 (39.4 ~ 59.3)
6.3 27.8 46.4 36.3 (26.6 ~ 47.1)
9.9 23.3 56.5 38.5 (13.1 ~ 72.2)
3.7 24.9 68.9 43.2 (37.4 ~ 49.1)
2.7 14.6 56.4 35.6 (30.0 ~ 41.7)
4.2 23.3 60.7 42.5 (36.1 ~ 49.2)
3.8 27.8 60.7 40.6 (33.9 ~ 47.7)
4.6 23.3 75.9 41.0 (30.0 ~ 53.0)





participants Median (%) Minimum (%) Maximum (%)
Pooled prevalence
(%) (95% CI)
Hypercholesterolemia (TC) ≥ 18 y 9 143350 7.7 2.5 41.8 7.9 (4.6 ~ 13.2)
≥ 30 y 10 41366 10.8 4.9 48.1 12.5 (5.8 ~ 25.0)
Total 19 184716 8.2 2.5 48.1 10.1 (5.8 ~ 16.9)
Hypertriglyceridemia (TG) ≥ 18 y 9 143350 15.3 4.5 36.9 13.7 (10.7 ~ 17.4)
≥ 30 y 10 41367 18.8 11.7 44.5 22.1 (16.0 ~ 29.7)
Total 19 184717 17.1 4.5 44.5 17.7 (14.0 ~ 22.1)
Mixed hyperlipidemia (TC + TG) ≥ 18 y 3 11249 6.5 1.9 4.2 4.8 (2.4 ~ 9.2)
≥ 30 y 1 2102 - - - -
Total 4 13351 6.4 1.9 8.3 5.1 (3.1 ~ 8.2)
Low blood high-density lipoprotein
cholesterol (HDL-C)
≥ 18 y 9 143350 6.9 0.2 57.3 11.0 (6.9 ~ 16.9)
≥ 30 y 9 38129 10.1 1.6 32.8 11.0 (6.6 ~ 17.9)
Total 18 181479 10 0.2 57.3 11.0 (8.0 ~ 15.0)
High blood low-density lipoprotein
cholesterol (LDL-C)
≥ 18 y 5 130826 3.1 2.3 67.5 7.6 (2.1 ~ 24.3)
≥ 30 y 7 29843 12.2 1.7 21.3 9.7 (4.5 ~ 19.8)
Total 12 160669 8.8 1.7 67.5 8.8 (4.1 ~ 17.8)
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moting healthy diet and lifestyles are equally import-
ant in designing and implementing relevant public
health strategies.
We calculated and compared the pooled estimates of
dyslipidemia prevalence in age groups over 18 years and
over 30 years. No significant difference was found be-
tween these age groups across different types of dyslipid-
emia conditions. However, trends of higher prevalence
of TC, TG, and LDL-C abnormalities were observed in
studies of older participants (≥30 years old) compared
to those studies that enrolled younger participants
(≥18 years old). We observed the highest estimate at
49.3% (95% CI: 39.4-59.3) among all of the pooled
prevalence estimates in people over 30 years old in the east-
ern region of China. Another study in China concluded that
greater burden of diet-related chronic conditions including
dyslipidemia has been observed in economically vibrantTable 5 Dyslipidemia awareness and treatment rates
Groups Number of studies Total numberof participants Media
Awareness rate
Male 3 28021 25
Female 3 28439 31.2
Total 4 59807 28.9
Treatment rate
Male 2 26620 7.2
Female 2 26467 10.9
Total 2 53087 9.1and highly urbanized areas [49], which are predominantly
in the eastern coastal region. More economically developed
areas tend to have better access to health care facilities,
which might have contributed to diagnosis and hence
higher reported prevalence rates in these studies among
populations in the eastern region of China.
The systematic review showed that dyslipidemia is
more common in men than in women, which is consist-
ent with the findings from American population-based
studies [50,51]. There were no significant differences in
awareness, treatment, and control rates between the
groups of men and women in China. However, studies
conducted in the US showed that dyslipidemia was
treated and controlled less often in men than in women
[50]. A possible explanation for the higher dyslipidemia
prevalence observed in men could be their higher prob-
ability of cigarette smoking, alcohol, and consumption of
foods high in cholesterol.n (%) Minimum (%) Maximum (%) Pooled prevalence(%) (95% CI)
12.4 25.3 20.1 (11.2 ~ 33.3)
14.7 32.9 25.2 (13.0 ~ 43.1)
13.5 29.8 24.4 (14.4 ~ 38.4)
6.8 7.6 7.6 (7.3 ~ 7.9)
9.2 12.5 10.6 (7.8 ~ 14.2)
8.4 9.7 8.8 (7.7 ~ 10.0)
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review were generally good, thus the sensitivity analysis
did not demonstrate much difference in the results of
meta-analyses when the studies with the lowest quality
scores were removed in the analyses. We believe our
searches were comprehensive, although the asymmetric
funnel plots suggested the possibility of publication bias.
The moderate heterogeneity observed could come from
the different study settings and populations. We investi-
gated possible sources and performed subgroup analyses,
but that still inadequately explained the heterogeneity
findings in this study. The recent research of heterogen-
eity suggested that I2 estimates need to be interpreted
with caution when a meta-analysis only includes a lim-
ited number of events or trials, in particular when the
number of studies for further subgroup analyses is small
[52]. Nevertheless, these uncertainties indicate the need
of a higher-quality national survey with larger samples
with better represented coverage across China.
Our study has some limitations. First, all the included
studies were published after 2007 as we used the
Chinese Guidelines on Prevention and Treatment of
Dyslipidemia in Adults, published in 2007, as the diag-
nosis criteria [2]. Studies published before 2007 were
based on a different set of diagnosis criteria, and there-
fore have not been included in our meta-analyses.
Secondly, we could not investigate the differences in
dyslipidemia prevalence between rural and urban areas
due to the limited information reported in the included
studies. Furthermore, we would like to highlight that the
meta-analysis results on awareness, treatment, and
control rate need to be interpreted with caution, as the
number of studies reporting the relevant data are rela-
tively small.
Conclusions
The pooled estimate of dyslipidemia prevalence among
Chinese adults was 41.9%, and hypertriglyceridemia
(TG) is the most prevalent dislipidemia condition. The
prevalence of dyslipidemia in males was higher than in
females. Our study also showed low dyslipidemia aware-
ness, treatment, and control rates in China.
Additional file
Additional file 1: Forest plots and funnel plots of different sets of
analyses are available as appendices at PHM online.
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